Trials / Completed
CompletedNCT02052609
A Phase 3 Clinical Study of KHK 4827
An Extension Study of KHK4827 in Subjects With Plaque Psoriasis (Psoriasis Vulgaris, Psoriatic Arthritis), Pustular Psoriasis (Generalized) and Psoriatic Erythroderma
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 155 (actual)
- Sponsor
- Kyowa Kirin Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to evaluate the safety and efficacy of long-term exposure to KHK4827 in subjects with plaque psoriasis (psoriasis vulgaris, psoriatic erythroderma) who have completed Study 4827-003 (Study 003)and in subjects with pustular psoriasis (generalized) or psoriatic erythroderma who have completed the Study 4827-004 (Study 004).
Conditions
- Psoriasis Vulgaris
- Psoriatic Arthritis
- Pustular; Psoriasis, Palmaris Et Plantaris
- Psoriatic Erythroderma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KHK4827 140mg SC | Experimental1:KHK4827 140mg subcutaneous injection |
| DRUG | KHK4827 210mg SC | Experimental2:KHK4827 210mg subcutaneous injection |
Timeline
- Start date
- 2014-02-01
- Primary completion
- 2015-01-28
- Completion
- 2016-07-04
- First posted
- 2014-02-03
- Last updated
- 2023-08-25
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT02052609. Inclusion in this directory is not an endorsement.